OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions ...

Tiotropium, the first-choice long-acting bronchodilator in COPD, has been studied in severe asthmatics and in COPD patients with a history of asthma, showing an additional bronchodilator effect on ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

These data strengthen our belief that ensifentrine’s novel bronchodilator and non-steroidal ... a dose-ranging trial with glycopyrrolate, a long-acting muscarinic antagonist (“LAMA ...

GSK's new long-acting drug candidate for severe asthma ... dose inhaled corticosteroids (ICS), plus at least one additional bronchodilator therapy. "As a physician, it is encouraging to see ...

Primary care practices were randomised to use an electronic health record based CDSS, which recommended a specific guideline ...

Ensifentrine is billed as a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), and is thought to combine bronchodilator ... with either long-acting muscarinic ...

The California Horse Racing Board has filed official complaints against trainer Monty Arrossa over positives for the same substance that has wrought sweeping allegations against trainers Heath Taylor ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

SAUL LOEB/AFP via Getty Images In an email to Newsweek on Tuesday, a White House official confirmed that the "Acting doge administrator ... DOGE Administrator for as long as it could, but the ...